Although we could not clarify the underlying mechanisms that govern the involvement of IKZF1 deletion and biallelic loss of CDKN2A in higher BTZ sensitivity, it should be noted that the underlying mechanisms that contribute to poor therapeutic outcome in ALL with IKZF1 deletion remain to be elucidated [45]. This evidence concerns the gene CASC3 and acute lymphoblastic leukemia.